Shares of IDEXX Laboratories IDXX were unchanged after the company reported Q3 results.
Quarterly Results
Earnings per share increased 36.29% over the past year to $1.69, which beat the estimate of $1.42.
Revenue of $721,789,000 rose by 19.24% year over year, which beat the estimate of $669,450,000.
Outlook
IDEXX Laboratories hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Oct 29, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/wmvg5y3j
Price Action
Company's 52-week high was at $444.96
52-week low: $168.65
Price action over last quarter: Up 7.88%
Company Overview
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. Idexx gets about 38% of its revenue from outside the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.